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The web of causation is closing in on EB virus in its relation to certain conditions.
In heterophile positive infectious mononucleosis the web of causation seems estab-
lished beyond any reasonable doubt (1-3). The evidence derived from prospective
serological studies that EBV antibody is regularly absent prior to infectious mono-
nucleosis and regularly appears during illness (4-7) is supported by the demonstra-
tion of EBV-specific IgM antibody indicative of a primary infection (8-10), by
identification of the virus in lymphocytes cultured from the blood (1) by isolation
of the virus from the throat (11-13), and by suggestive experimental evidence of in-
fectious mononucleosis in squirrel monkeys (14) and gibbons (15) inoculated with
EBV or EBV-infected cells. The immunological events that turn infectious mono-
nucleosis on and turn it off are not so clear, although evidence is rapidly accumu--
lating on these questions. Figure 1 presents a working schema of pathogenesis.
EB virus appears to enter the oropharynx in young adults, probably thru kissing,
and multiplies locally producing a lytic and persistent infection (16). It enters the
blood stream and possibly the gut although the latter has not yet been established.
Lymphocytes of the B-type are infected and a nonproductive infection of long dura-
tion is established. Some of these transformed B cells may contribute early to the
atypical lymphocytosis. Current evidence then suggests that there is mixed lympho-
cyte reponse of T cells to B cells altered by an EBV-membrane induced antigen.
This results in T cell proliferation (17), transformation, and a major outpouring
of atypical lymphocytes. Lymphocytes from acute cases of infectious mononucleosis
have also been found to cause stimulation of convalescent leukocytes from the same
'From the WHO Serum Reference Bank. The work in the author's laboratory was carried
out with Dr. J. C. Niederman under grants from the National Cancer Institute (CA-12952),
National Institute of Allergy and Infectious Diseases (AI-0873 1) and the World Health
Organization.
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FIG. 1. Working schema of pathogenesis. The relation to Burkitt lymphoma is derived from
Epstein and Achong (16).
persons indicating the presence of a new surface antigen during acute illness
(18-19). While it seems most probable that the immunologic response of the T
cells is the major cause of the atypical lymphocytes of infectious mononucleosis
(17-20)-this needs additional proof. The activated T cells may cause the destruc-
tion of the EBV-infected B cells, as has been shown in vitro and in other viral
systems (21, 22). This destruction may account for the inability to demonstrate
EBV or its genome in fresh lymphocytes from acute cases of infectious mono-
nucleosis.' That not all B lymphocytes are destroyed is shown by the presence of
a sufficient number of infected cells to initiate a long-term culture of EBV-infected
B lymphocytes, perhaps through secondary infection of other B cells in vitro when
immunological inhibitors in the serum are removed (16). The mechanism of
heterophile production is still unexplained but the knowledge that its appearance
is most common in EBV infections of young adults (2) and that the age of the
donor of the lymphocytes is important in the degree of expression and release of
EBV suggest avenues of investigation using new techniques capable of identifying
in vitro antibody and antigen production by lymphocytes from different ages. For
example, EBV-infected fetal lymphocytes do not have demonstrable VCA antigen
but do contain EB virus nuclear antigen (EBNA) (23) and complement fixing
antigen (13). The EB nuclear antigen is demonstrated by the fixation of comple-
ment in an indirect immunofluorescent test (23). In lymphocytes from young adults
and from marmosets EBV may mature more fully releasing antigens to other
lymphocytes. Hetcrophile antibody may be produced in response to membrane-in-
2 Very recently Zur Hausen et al. have demonstrated EBV genome in the peripheral
lymphocytes of 2 severe case of infectious mononucleosis (Zur Hausen, H., Schulte-Holthausen,
H., Wolf, H., Dorries, K., and Egger, H., Attempts to detect virus-specific DNA in human
tumors. II. Nucleic acid hybridizations with complementary RNA of human herpes group
viruses, Int. J. Cancer 13, 657-664, 1974).EB VIRUS, INFECTIOUS MONO AND CANCER
duced changes of EBV which may express themselves more fully in lymphocytes
of young adults than in younger children or in fetal lymphocytes. There is no ex-
perimental data yet in support of this concept.
The causal relationship of EB virus to Burkitt's lymphoma is more indirect than
in infectious mononucleosis because of the difficulty in mounting a meaningful pro-
spective study in which temporal relationships between EBV and the tumor can
be recognized. However, a pilot investigation of this type has been launched in
the West Nile area of Africa involving 1122 children who are being serially fol-
lowed and bled (24).3 A large number of persons are needed because of the rela-
tively low incidence of Burkitt's lymphoma, averaging about 13 per 100,000 in
children ages 4-8 in this area. Furthermore, the prolonged follow-up required to
identify cases of Burkitt lymphoma make this a major undertaking. The evidence
currently supporting a causal role of EB virus in Burkitt lymphoma and its short-
comings, has been summarized in an excellent review by Miller (25) and synthe-
sized into a working hypothesis by Epstein and Achong (16). In African Burkitt
lymphoma, the major facts suggesting EB virus as the cause are: (I) the presence
of EBV antibody in the sera of almost all cases; (2) the demonstration of very
high antibody titers in the sera of 80% or more of the cases as compared to healthy
controls and most other lymphoproliferative diseases; (3) the breadth of the anti-
body response including antibodies to viral capsid, complement fixing, membrane,
and early antigens as well as neutralizing antibody; (4) the demonstration of the
EBV genome in freshly obtalned biopsy specimens of tumor tissue by nucleic acid
hybridization studies (26, 27) and/or of EB nuclear antigen (23) from a total
of about 120 cases; (5) the experimental production of reticulum cell sarcomas
in cotton-top marmosets using EBV-infected marmoset cells or cell-free EBV by
Shope et al. (28) with the ability to recover EBV from these tumor cells; and
similar results in owl monkeys (29); (6) the capacity of EB virus to transform
normal lymphocytes into cells with an infinite potential for proliferation in vitro.
This last property has been termed "immortalizing" factor by Miller (25) who
presents a detailed study of this event in this issue of The Yale Journal of Biology
and Medicine (p. 123). Here the question of the expression of EB virus in 3 lym-
phoblastoid lines is examined. The results suggest that the capsid antigens are dis-
continuous in expression in contrast to the complement fixing and nuclear antigens
which are continuously expressed. An understanding of the behavior of EBV in
productive and nonproductive cell lines may provide clues to their in vivo
counterparts.
The web of causation is thus tightening on the causal relation of EB virus to
Burkitt lymphoma. It comes close to fulfilling the Henle-Koch postulates. There
is also increasing evidence of the oncogenity of herpes viruses in several animal
species: of lymphoma in New World monkeys inoculated with herpes saimiri or
ateles viruses, of Marek's disease, a herpes-associated lymphoproliferative disease
in chickens, of Lucke adeno carcinoma in frogs, and of herpes sylvilacus in cotton-
tail rabbits which produces lesions resembling a malignant lymphoma.` But there
3Thirty-five thousand children are now under study and Burkitt lymphoma has occurred
in 5 thus far (R. Morrow, personal communication).
4See "Oncogenesis and Herpesviruses," (P. M. Biggs, G. deThe and L. N. Payne Eds.),
IARC (Lyon 1972) and "The Herpesviruses," (A. Kaplan Ed.), Academic Press, New
York and London, (1973) for information on herpes viruses of man and animals and
their oncogenic potential.
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are problems in fully accepting EBV as the sole cause of Burkitt lymphoma. First,
evidence suggesting the presence of a RNA tumor virus in Burkitt lymphoma cells
by Kufe et al. (30) raises the question as to whether this virus and EBV may
be working in concert, or one activating the other, or one or both being only passen-
ger viruses. Second, biopsies from a few cases of African Burkitt lymphoma have
lacked detectable EBV genome (23-27) and antibody has been absent in the sera
of 2 cases. Furthermore, in American patients diagnosed histologically as Burkitt
lymphoma EBV antibody has been absent from the serum of 19% of the cases
in 2 separate studies (31-32), present but without elevation in titer in many others
(31-33), and without demonstrable EBV genome in the biopsy tissues of 4 Ameri-
can Burkitt lymphoma cases (34). In addition to EB virus as a causative agent,
there is strong epidemiologic evidence incriminating malaria as an important cofactor
in African Burkitt lymphoma to account for the high incidence of Burkitt lympho-
mas in Africa and New Guinea (35, 36). The mechanism for this enhanced suscep-
tibility is not clear but might be due to antigen-antibody malarial complexes (block-
ing factors) interfering with cell-mediated (T lymphocyte) responses to EBV
infection resulting in viral persistence and tumor formation. The study of cell-medi-
ated immunity in Burkitt lymphoma is just beginning. Fass et al. (37) have shown
delayed hypersensitivity reactions in Burkitt lymphoma patients exposed to auto-
logous tumor cell extracts, but it is not known whether these reactions are directed
against EBV-induced antigens or not. The positive reactions correlated with sus-
tained remissions.
The web of causation for EBV in nasopharyngeal carcinoma is of the same gen-
eral order as in African Burkitt lymphoma: EBV antibody is almost universally
present in the serum, the antibody titer is very high in 80% of the cases and the
EBV genome has been demonstrated not only in the lymphocyte infiltrated tumor
(26) but in the epithelial cells themselves (38). A lead as to how EB virus pro-
duces infection in epithelial cell in vivo when it is usually limited to lymphocytes
in vitro has been provided by the demonstration that hybrid cells consisting of
an epithelial line and BL lymphocytes fused with Sendai virus, and stimulated by
BUDR, support the persistence of EBV genome (39). The possible existence of
an in vivo fusion factor has been suggested by the occurrence of elevated antibody
titers to herpes simplex type 1 (40a) and to parainfluenza type 3 viruses (40b)
in sera from cases of nasopharyngeal cancer.
EB virus and a cofactor virus producing fusion are 2 potential ingredients in
the causation of nasopharyngeal cancer. A third important ingredient is genetic
susceptibility. It was early recognized that persons of Chinese descent, especially
from southern China, were at 10-50 times the risk of developing nasopharyngeal
cancer than caucasians in the same environment (41, 42). This high susceptibility
held true even when such Chinese lived in Australia (43), New South Wales (44),
or Hawaii (45). Important support for this genetic role has recently been derived
by Simons et al. (46) in 2 carefully controlled analyses of human leukocyte antigen
types in nasopharyngeal carcinoma. They found there was a significant increase
in the proportion of Chinese patients with nasopharyngeal cancer (NPC) in whom
less than 2 second locus antigens were detectable as compared to Chinese without
NPC. In addition they found a significant elevation in the frequency of HL-A2
antigen in Chinese patients with NPC as compared to Chinese persons without NPC.
A higher frequency of raised antibody titers to EB virus and a higher geometric
mean antibody titer have also been found in patients with Hodgkin's disease
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(47-51), systemic lupus erythematosus (52), and sarcoidosis (53, 54) than in com-
parable healthycontrols. Some investigators, however, have failed to find elevated
EBV titers in SLE (55, 56); the differences may be of a technical nature or related
to the activity of the disease at the time the sample was taken (57). In systemic
lupus erythematosis, significant elevations in rubella, parainfluenza, and measles
viral antibody titers as compared to matched controls have also been found (52,
58-60), and the first two antibodies have also been raised over matched controls
in patients with sarcoidosis (54). In contrast to this, antibody titers to influenza
A and B, cytomegalovirus, respiratory syncytial, herpes simplex, adenoviruses, and
other viruses have not been raised in these two conditions. It should be emphasized
that the frequency, height, and breadth of EBV antibody response in Hodgkin's
disease, SLE, and sarcoidosis have been less than in Burkitt lymphoma (BL) or
nasopharyngeal carcinoma (NPC). For example, only 30-40% of patients with the
3 former conditions have elevated EBV antibody titers as compared to 60-80%
in NPC and BL and the geometric mean titer in those with antibody is only'/4
to'/, of that found in the 2 malignancies. There is some evidence that HLA differ-
ences may play a role in Hodgkin's disease (50, 61, 62) and in systemic lupus
erythematosus (63), and that a serum inhibitor of cell-mediated immunity may be
present in sarcoidosis (64). The genome of EBV was not detected in the biopsy
tissues of 4 American patients with Hodgkin's disease (34, 65). More search for
the genome of EBV and for EBV nuclear antigen must be made in tissues of
Hodgkin's disease and other conditions with high EBV titers before any conclusion
can be drawn. At present, the relationship of EB and other viruses to the patho-
genesis of Hodgkin's disease, SLE, and sarcoidosis is much weaker than that of
EBV to Burkitt lymphoma and nasopharyngeal cancer. The raised antibody titers
may be secondary to depressed cell-mediated immunity and the viruses may play
no role in causation. Skepticism has recently been expressed on the causative role
of EBV and Hodgkin's disease (50) especially as antibody elevations occur only
in certain types, mainly in lymphocyte depletion and mixed-cellularity types. How-
ever, in diseases of unknown causation, it is important to explore every lead carefully
before making premature decisions to exclude a possible causative agent.
The presence of high EBV antibody titers in all these diseases suggests an anti-
genic stimulation by viral persistence and/or reactivation. The absence of elevated
antibody titers under certain conditions is compatible either with the absence of
viral activity or with an excess of viral antigen over antibody, such that immune
complexes form which reduce the measurable antibody level. This phenomenon
has been suggested to account for the lower EBV antibody titers during the active
phases of SLE (52) and in immune complex nephritis (66). Low or absent circu-
lating antibody has also been observed in mice in lymphocytic choriomeningitis,
in murine leukemia, and in lactic acid dehydrogenase-virus immune complex
glomerulonephritis (67-70).
A selected impairment in cell-mediated immunity has been proposed as a com-
mon denominator in EBV-associated infections (71, 72) resulting in virus persis-
tence or reactivation. The mechanism by which this might occur is not entirely
clear but increasing attention is being directed to the T lymphocyte in its role in
the recognition and control of viral infections and of their reactivation. The T
lymphocytes may be deficient in numbers, tied up in other tasks (antigenic competi-
tion), genetically lack appropriate receptors for EBV or EBV-induced antigens,
be blocked in their task by serum inhibitors, or rendered ineffective by immuno-
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suppressant drugs. Suppressor T cells may block the action of other T cells. Inten-
sive study of cell-mediated immunity in EBV infections is in order with special focus
on whether T cells respond normally to EB virus in infectious mononucleosis,
Burkitt lymphoma and nasopharyngeal cancer as well as in other EBV-associated
conditions. A method for such stimulation has been published by Gerber and Lucas
(73). It has been recently shown that patients who are immunosuppressed during
renal transplantation or for therapeutic reasons excrete EB virus from the pharynx
more commonly than controls, and that the infection may be reactivated (74).
There is clearly an increased risk for certain types of cancer in persons given
immunosuppressant drugs in high dosage (75). This is of the order of 35 times
higher than normal, particularly for reticulum-cell sarcoma.
The presence of high antibody levels to certain viruses thus appears to be associ-
ated with an increased risk to some malignancies, to chronic diseases like SLE
and sarcoidosis, as well as to chronic neurologic diseases like progressive multifocal
leukoencephalopathy (papovavirus), subacute sclerosing panencephalitis and multi-
ple sclerosis (both associated with measles virus). The critical evidence lacking
is whether these high titers precede the disease and thus play a causal role, accom-
pany the disease expressing a common immunologic defect with the real cause of
the disease, or follow in the wake of the disease as a consequence of
depressed cell-mediated immunity induced by the disease itself. This temporal
sequence may vary in different diseases. The retrospective approach also fails to
identify other possible diseases associated with high antibody titers and does not
permit assessment of risk factors. It is important now to mount large scale prospec-
tive seroepidemiologic studies which would (1) identify healthy individuals who
have high antibody titers to EBV, rubella, parainfluenza, measles, papavo virus,
herpes type 2 viruses etc. and/or have impaired lymphocyte responses to these
viruses;5 (2) seek evidence of viral excretion and persistence; (3) follow such per-
sons and matched controls, who have normal antibody levels, for the occurrence
of cancer, chronic diseases, and neurological disorders, especially those of unknown
cause associated with defects in cell-mediated immunity,; or in which immunc com-
plexes are suspected as playing a role in the pathogenesis; (4) carry out intensive
virological and immunological studies when a chronic disease occurs, including a
search for the virus or viral genome in affected tissues. The results should be com-
pared with matched controls, whenever possible. If one takes the total incidence
of all of the malignant and chronic diseases in which viruses may play a role, then
the return from such a costly venture should make it justifiable and make the popu-
lation base manageable. The populations served by large health plans caring for
all ages would be an admirable start because of their accessibility to bleeding on
entry into the plan and at periodic intervals thereafter and because of the possibility
of good clinical surveillance. Indeed, it might not be necessary to carry out viral
antibody tests until a disease develops provided frozen serum and lymphocyte sam-
ples were available prior to this time from the patient and from suitable controls.
From the epidemiologist's standpoint there are factors that might obscure a true
causal relationship between EB virus and the chronic conditions with which it is
'Prospective analysis of cancer and chronic diseases according to their HLA type should
also be included, if possible.
'The major ones of current interest are lymphomas, leukemia, cervical and penile cancer,
SLE, rheumatoid arthritis, sarcoidosis, immune complex, kidney disease, chronic neurological
diseases.
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associated. EBV might be a causal factor in one setting but not in another. For
example, it might cause African Burkitt lymphoma but not American Burkitt
lymphoma; it might be a cause of Hodgkin's disease in the young age group but
not in the old; it might be causally related to some cases of systemic lupus erythe-
matosus but not to others. There may be several strains of EBV some of which
are oncogenic and some of which are not. As a candidate oncogenic virus for 2
special malignancies, Burkitt lymphoma in Africa and nasopharyngeal carcinoma
in Chinese, EB virus appears to have won the primary (76). Full acceptance will
require much more evidence to satisfy everyone. Virologically, this includes further
attempts to produce lymphomas in primates using purified EBV derived from a
Burkitt lymphoma and in the presence or absence of concomitant experimental
malaria; assessment of the role, if any, of an RNA virus in this setting, and ex-
panded efforts to identify the EBV genome and/or nuclear antigen in various tis-
sues from patients with lymphoma, NPC, other cancers, and controls. Epidemio-
logically, prospective surveys must establish that EBV infection and high antibody
titers precede the disease and that such high titers are associated with a higher
risk of tumor than in those with normal antibody titers; control of a cofactor such
as malaria in Burkitt lymphoma or a myxovirus infection in NPC should decrease
the incidence of the associated tumor. Genetically, the relation of HLA and similar
antigens to NPC must be clarified and the role of these genetic attributes explored
in other conditions associated with high EBV antibody levels.
Immunologically, the mechanism of viral persistence and/or reactivation in these
conditions need further analysis, particularly the specific responses of lymphocytes
to EBV, myxoviruses, and malaria. Therapeutically, the possible effect of transfer
factor derived from lymphocytes of EBV-immune subjects should be cautiously
explored in controlled trials of Burkitt lymphoma and nasopharyngeal carcinoma
as compared with transfer factor from the lymphocytes of persons lacking EBV
antibody.
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